Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
786.13 USD | +1.09% |
|
+0.99% | +1.94% |
03:38pm | Sector Update: Health Care | MT |
11:04am | Öhman Health and New Technology Fund Rises 3.9% in June - Camurus Surges After Eli Lilly Partnership | FW |
Business description: Eli Lilly and Company
- endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.4%);
- immunology diseases (9.8%);
- neurology (3.3%): primarily drugs used in treating depression and schizophrenia;
- other (2%).
Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
Number of employees: 47,000
Sales by Activity: Eli Lilly and Company
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Discovery, Dev., Manufacturing, Marketing, and Sales of Pharmaceutical Products | 24.54B | 28.32B | 28.54B | 34.12B | 45.04B |
Geographical breakdown of sales: Eli Lilly and Company
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States (U.S.) | 14.23B | 16.81B | 18.19B | 21.79B | 30.38B |
Europe | 4.19B | 4.78B | 4.3B | 6.17B | 6.92B |
Rest of world | 2.42B | 2.7B | 2.85B | 2.95B | 4.27B |
Japan | 2.58B | 2.37B | 1.75B | 1.67B | 1.81B |
China | 1.12B | 1.66B | 1.45B | 1.54B | 1.66B |
Executive Committee: Eli Lilly and Company
Manager | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 2024-09-08 |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | 50 | 2021-05-16 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 2023-10-15 |
Composition of the Board of Directors: Eli Lilly and Company
Director | Title | Age | Since |
---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 65 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 2009-03-31 |
Director/Board Member | 53 | 2011-12-11 | |
David Ricks
CHM | Chairman | 57 | 2017-05-31 |
William Kaelin
BRD | Director/Board Member | 67 | 2012-06-03 |
Juan Luciano
BRD | Director/Board Member | 63 | 2016-01-31 |
Jamere Jackson
BRD | Director/Board Member | 55 | 2016-09-30 |
Director/Board Member | 64 | 2021-01-24 | |
Kimberly Johnson
BRD | Director/Board Member | 52 | 2021-02-15 |
Director/Board Member | 62 | 2022-05-14 |
Holdings: Eli Lilly and Company
Name | Equities | % | Valuation |
---|---|---|---|
6,097,792 | 1.49% | 50,889,367 $ | |
PROQR THERAPEUTICS N.V. 16.37% | 16,895,100 | 16.37% | 34,466,004 $ |
4,000,000 | 7.19% | 18,800,000 $ | |
PEIJIA MEDICAL LIMITED 2.98% | 19,952,740 | 2.98% | 16,445,048 $ |
Company details: Eli Lilly and Company

Group companies: Eli Lilly and Company
Name | Category and Sector |
---|---|
Lilly Asia Ventures Fund II LP
![]() Lilly Asia Ventures Fund II LP Investment ManagersFinance Lilly Asia Ventures Fund II LP invests in companies located in China and the United States. The fund targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices, and diagnostics. It provides financing in the form of equity for seed, early and growth stage capital requirements. |
Investment Managers
|
Eli Lilly (Suisse) SA |
Miscellaneous Commercial Services
|
Eli Lilly Kinsale Ltd.
![]() Eli Lilly Kinsale Ltd. Pharmaceuticals: OtherHealth Technology Eli Lilly Kinsale Ltd., part of Eli Lilly & Co., is a company headquartered in Kinsale, Ireland, that manufactures medicines. |
Pharmaceuticals: Other
|
Lilly Ventures Fund I LLC
![]() Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Vostok SA |
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+1.09% | +0.99% | -15.60% | +137.71% | 698B | ||
+0.02% | +0.11% | +5.90% | -12.68% | 375B | ||
+0.41% | -0.10% | +13.39% | +24.36% | 335B | ||
-1.53% | +0.35% | -54.14% | +9.26% | 313B | ||
+0.89% | -0.04% | +6.30% | -20.36% | 259B | ||
-0.16% | -0.89% | +0.47% | +17.53% | 240B | ||
+0.21% | -0.27% | -13.25% | -7.10% | 217B | ||
+2.88% | +1.86% | -33.42% | -11.01% | 204B | ||
-0.21% | +0.01% | -6.03% | +19.81% | 160B | ||
-0.41% | +0.67% | -8.04% | -51.81% | 146B | ||
Average | +0.30% | +0.74% | -10.44% | +10.57% | 294.8B | |
Weighted average by Cap. | +0.39% | +0.50% | -10.60% | +31.62% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
- Company Eli Lilly and Company
Select your edition
All financial news and data tailored to specific country editions